1. Academic Validation
  2. A general strategy towards personalized nanovaccines based on fluoropolymers for post-surgical cancer immunotherapy

A general strategy towards personalized nanovaccines based on fluoropolymers for post-surgical cancer immunotherapy

  • Nat Nanotechnol. 2020 Dec;15(12):1043-1052. doi: 10.1038/s41565-020-00781-4.
Jun Xu 1 Jia Lv 2 Qi Zhuang 1 Zongjin Yang 1 Zhiqin Cao 1 Ligeng Xu 1 Pei Pei 3 Chenya Wang 1 Hanfei Wu 1 Ziliang Dong 1 Yu Chao 1 Chao Wang 1 Kai Yang 3 Rui Peng 4 Yiyun Cheng 5 6 Zhuang Liu 7
Affiliations

Affiliations

  • 1 Institute of Functional Nano & Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices, Soochow University, Suzhou, China.
  • 2 South China Advanced Institute for Soft Matter Science and Technology, South China University of Technology, Guangzhou, China.
  • 3 State Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection and School for Radiological and Interdisciplinary Sciences (RAD-X), Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou, China.
  • 4 Institute of Functional Nano & Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices, Soochow University, Suzhou, China. rpeng@suda.edu.cn.
  • 5 South China Advanced Institute for Soft Matter Science and Technology, South China University of Technology, Guangzhou, China. yycheng@mail.ustc.edu.cn.
  • 6 Shanghai Key Laboratory of Regulatory Biology, School of Life Sciences, East China Normal University, Shanghai, China. yycheng@mail.ustc.edu.cn.
  • 7 Institute of Functional Nano & Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices, Soochow University, Suzhou, China. zliu@suda.edu.cn.
Abstract

Cancer metastases and recurrence after surgical resection remain an important cause of treatment failure. Here we demonstrate a general strategy to fabricate personalized nanovaccines based on a cationic fluoropolymer for post-surgical Cancer Immunotherapy. Nanoparticles formed by mixing the fluoropolymer with a model antigen ovalbumin, induce dendritic cell maturation via the Toll-like Receptor 4 (TLR4)-mediated signalling pathway, and promote antigen transportation into the cytosol of dendritic cells, which leads to an effective antigen cross-presentation. Such a nanovaccine inhibits established ovalbumin-expressing B16-OVA melanoma. More importantly, a mix of the fluoropolymer with cell membranes from resected autologous primary tumours synergizes with checkpoint blockade therapy to inhibit post-surgical tumour recurrence and metastases in two subcutaneous tumour models and an orthotopic breast Cancer tumour. Furthermore, in the orthotopic tumour model, we observed a strong immune memory against tumour rechallenge. Our work offers a simple and general strategy for the preparation of personalized Cancer vaccines to prevent post-operative Cancer recurrence and metastasis.

Figures
Products